drugset
drugset / Trial / NCT07241234

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria

NCT07241234 ↗

Phase 1 Recruiting 20 enrolled Agios Pharmaceuticals, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).

Timeline

Start
2026-04-17
Primary completion
2028-01-17
Completion
2028-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject AG-181 Unknown — —

Indications

phenylketonuria